GlassScriptPhysician profile
Ramon A Sandoval
NPI 1316032014
$16,083.95
in general payments reported to CMS, 2019-2025
50 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,587 · 2020: $1,865 · 2021: $2,690 · 2022: $2,681 · 2023: $1,921 · 2024: $1,901 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,241 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,240.54 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,719.42 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,449.67 | 2020-2025 | Vraylar, Creon, Linzess |
| Amgen INC. | $1,294.94 | 2019-2025 | Evenity, Repatha, Repatha |
| Glaxosmithkline, LLC. | $1,200.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,061.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $972.09 | 2019-2025 | Ozempic, Rybelsus |
| Ironwood Pharmaceuticals, INC | $760.60 | 2020-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $660.19 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $609.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $470.39 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Lilly USA, LLC | $451.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $450.42 | 2019-2024 | |
| Pfizer INC. | $399.34 | 2019-2025 | |
| Exact Sciences Corporation | $398.24 | 2023-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $286.51 | 2019-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.